作为一种改善癌症预后的抗炎剂的素:一种治疗性重新定位的前景
Sigal Matza Porges1, Oded Shamriz2, Shlomo Z Ben-Sasson3
1Department of Human Genetics, Institute for Medical Research the Hebrew University of Jerusalem, Jerusalem, Israel; Department of Medical Laboratory Sciences, Jerusalem Multidisciplinary College, Jerusalem, Israel.
Seminars in oncology
|November 22, 2025
概括
抗炎药物科尔奇辛在癌症治疗中表现有前途,它通过向关键癌症途径并减少治疗副作用来治疗癌症. 这一观点探讨了其在瘤学中的潜力.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 炎症 炎症是一种炎症.
背景情况:
- 科尔奇辛是一种成熟的抗炎药物,具有很长的使用历史.
- 癌症生物学涉及复杂的途径,包括炎症,血管新生和自.
- 与治疗相关的并发症,如心血管疾病,是癌症护理的重大挑战.
研究的目的:
- 突出科尔奇辛作为瘤学中的潜在治疗剂.
- 综合有关菌素与癌症生物学相关的机制的证据.
- 讨论科尔奇辛在减轻癌症治疗副作用方面的作用.
主要方法:
- 文献审查和证据综合.
- 对colchicine的临床前和临床数据的分析.
- 科尔奇辛的分子点和途径的探索.
主要成果:
- 胆固醇向癌症的中心途径:慢性炎症,血管新生,细胞骨重塑和自.
- 有证据表明,素可以减轻与治疗相关的并发症,包括心血管疾病.
- 该药物的抗炎和抗癌特性得到了现有研究的支持.
结论:
- 科尔奇辛为瘤学应用提供了一个有希望的,可访问的治疗选择.
- 需要进一步研究菌素在癌症治疗中的有效性和安全性.
- 重新利用胆固醇可能为全面的癌症管理提供一种新的策略.
更多相关视频
相关概念视频
Drugs that Destabilize Microtubules
3.6K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.6K
Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
469
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
469
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K


